SignalGrid
Institutional NLP Intelligence
Market OverviewCompany MonitorSector IntelligencePortfolioAlertsThemesEventsAskReportsMethodologyAdmin
Coverage
503 companies monitored
12,842 documents processed
97% source coverage
Last updated May 19, 2026 9:35 AM ET

Health Care Intelligence

Health Care is bifurcated: GLP-1 language remains exceptional, while managed care and litigation references lifted sector risk breadth.

XLV sector ETF·3 prototype constituents·ETF 5D +0.1%
Average sentiment
59
-0.7 pts
Breadth 33% · top positives LLY, JNJ, UNH
Risk score
59
+33.0 pts
Risk breadth 33% · emerging risks Reimbursement risk, Drug pricing, Litigation
News volume
76
+17.0 pts
Abnormal volume 67
Sentiment breadth
33%
-0.7 pts
Leading topics: GLP-1, Regulatory scrutiny, Healthcare utilization

Sector Summary

Data window 5D · 9 supporting sources

High confidence · 82

Health Care is bifurcated: GLP-1 language remains exceptional, while managed care and litigation references lifted sector risk breadth.

Leading topics: GLP-1, Regulatory scrutiny, Healthcare utilization
Emerging risks: Reimbursement risk, Drug pricing, Litigation
Top positive tickers: LLY, JNJ, UNH
Top negative tickers: UNH, JNJ, LLY
Signal Time Series
Selectable overlays with source-backed confidence context
Peer Signal Comparison
Company versus sector peers on sentiment, risk, and confidence
Topic Momentum Map
Momentum vs sentiment, sized by source count

Company Ranking Within Sector

Peer-level sentiment, risk, and confidence comparison.

TickerCompanySentiment5D changeRiskNews volumePrimary topicConfidence
UNHUnitedHealth Group Incorporated37-9.67986Regulatory scrutiny82
LLYEli Lilly and Company86+8.63984GLP-190
JNJJohnson & Johnson55-1.16058Regulatory scrutiny78

Topic Map

Topic drivers and emerging risks for the sector.

TopicCategorySentimentMomentumIntensityRiskSourcesSummaryTop source
GLP-1Strategic Theme889195th pctRisk 5689GLP-1 language remains one of the strongest positive narrative clusters in health care, with evidence centered on capacity additions and demand durability.src-LLY-1
Regulatory scrutinyRisk Theme298090th pctRisk 78132Regulatory scrutiny increased across mega-cap platforms, managed care, aerospace, and consumer technology.src-GOOGL-2
GLP-1 capacity and demand durabilityStrategic Theme909497th pctRisk 5629GLP-1 demand language remains exceptionally strong, with evidence quality supported by earnings commentary and high-reliability news.src-LLY-1

Sector Source Evidence

Documents contributing to the sector-level narrative.

PublishedSource typePublisherTitleSentimentRiskTopicsImportanceNoveltyReliabilityNLP contribution
May 18, 4:40 PMRegulatory DocumentAgency ReleaseUnitedHealth Group Incorporated: language monitor flags regulatory scrutiny as primary driver33Risk 77Regulatory scrutiny, Scale advantages8971High-11.2
May 18, 12:40 PMNewsDow Jones NewswiresUNH evidence update: Utilization pressure, policy scrutiny, and reimbursement risk37Risk 85Regulatory scrutiny, Scale advantages8674High-25.2
May 18, 8:40 AMEarnings TranscriptCompany Earnings CallUNH cross-source read-through for Managed Health Care41Risk 77Regulatory scrutiny, Scale advantages8377High-11.2
May 18, 3:40 PMEarnings TranscriptS&P Capital IQ TranscriptEli Lilly and Company: language monitor flags glp-1 as primary driver82Risk 37GLP-1, GLP-1 demand, capacity expansion,8774High+25.2
May 18, 11:40 AMNewsReutersLLY evidence update: Manufacturing scale-up and payer access discussion86Risk 45GLP-1, GLP-1 demand, capacity expansion,8477High+11.2
May 18, 7:40 AMPress ReleasePR NewswireLLY cross-source read-through for Pharmaceuticals90Risk 37GLP-1, GLP-1 demand, capacity expansion,8180High+25.2
May 18, 2:40 PMSEC FilingSEC EDGARJohnson & Johnson: language monitor flags regulatory scrutiny as primary driver51Risk 58Regulatory scrutiny, Medtech recovery6142High+5.8
May 18, 10:40 AMNewsBloombergJNJ evidence update: Litigation reserves and drug pricing pressure55Risk 66Regulatory scrutiny, Medtech recovery5845High-8.2
May 18, 6:40 AMRegulatory DocumentCourt Filing MonitorJNJ cross-source read-through for Pharmaceuticals59Risk 58Regulatory scrutiny, Medtech recovery5548High+5.8